Skip to main content
. Author manuscript; available in PMC: 2016 Aug 23.
Published in final edited form as: Leukemia. 2015 Jul 23;30(1):190–199. doi: 10.1038/leu.2015.194

Figure 6.

Figure 6

Selinexor (KPT-330) spares normal human hematopoietic cells engrafted into NSG mice. (a) Total counts of hCD45+ cells per femur and tibia in mice engrafted with cord blood hCD34+ cells before and after treatment with either vehicle or selinexor at 20 mg/kg for 4 weeks. (b) Percentage of hCD34+ and hCD34+/CD38 − cells in the bone marrow (BM) of established grafts treated with either vehicle or selinexor. (c) Distribution of human blood lineages in the BM of grafts treated with either vehicle or selinexor. Sel, Selinexor, BT, before treatment. n=6–9 mice per group; Error bars represent mean±s.e.m.; ***P < 0.0001 by Student’s t-test for comparison between the indicated groups.